Status:
WITHDRAWN
The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL
Lead Sponsor:
Leland Graves III, MD
Collaborating Sponsors:
University of Kansas
Conditions:
Osteoporosis
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine what effect teriparatide will have on vascular (blood vessel) compliance and osteoprotegerin (bone fluid)and RANKL levels (bone cells).
Detailed Description
Research subjects participation is about 6 months. Subjects will give themselves daily injections of teriparatide after instruction on technique.
Eligibility Criteria
Inclusion
- Postmenopausal women and men over the age of 40 who are starting therapy with teriparatide
Exclusion
- Patients with diabetes mellitus
- current smokers
- patients with a history of organ transplantation
- Patients currently of previously on glucocorticoid therapy within the past year
- Patients with serum creatinine above 1.5 mg/dl, patients with uncontrolled hypertension (BP 140/90 or greater)
- Patients ineligible for teriparatide therapy: History of metabolic bone disease other than osteoporosis
- History of radiation therapy
- Patients pregnant or nursing
- History of bone metastasis or skeletal malignancies
- History of hypercalcemia
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00347737
Start Date
June 1 2006
End Date
May 1 2008
Last Update
January 16 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160